The estimated adjusted relative risk of detecting BE was 10.6 (95% confidence interval, 6.0–18.8) for the Cytosponge-TFF3 group vs. the usual care in a 12-month follow-up, equating to 127 new BE cases (Cytosponge-TFF3) vs. 13 (usual care) [42]. The gene discussed is TFF3; the disease is Barrett esophagus.